Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series.

Journal of the National Comprehensive Cancer Network : JNCCN - 10 Nov 2025

Wotman Michael T, Khalaf Alexander, Wang Kaiwen, Meric-Bernstam Funda, Gillison Maura L, Akhave Neal, Kerrigan Kathleen, Ferrarotto Renata

Abstract excerpt

Trastuzumab deruxtecan (T-DXd) has shown efficacy in HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) recurrent/metastatic (R/M) secretory gland cancers of the head and neck. However, there are minimal published data regarding the use of T-DXd in HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-mutant tumors. This case series aimed to describe the clinical characteristics and outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Head and Neck Neoplasms

Share to Immunoconjugates

Share to Neoplasm Recurrence, Local

Share to Salivary Gland Neoplasms

Share to Trastuzumab

Source

Identifiers

PMID: 41213241
DOI: 10.6004/jnccn.2025.7104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series.PMID 41213241Read ↗

Targeting human EGFR 2 (HER2) in salivary gland carcinomaSemantic proximity Read ↗

Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial.Semantic proximity Read ↗

Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case reportSemantic proximity Read ↗

Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity.Semantic proximity Read ↗

ETV6-NTRK3 Gene fusion positive Secretory carcinoma Breast in a two year seven month old child with metastatic axillary lymph node: A case report and Review of literatureSemantic proximity Read ↗

Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes.Semantic proximity Read ↗

The genetic and immune features of salivary gland secretory carcinoma with high-grade transformation.Semantic proximity Read ↗

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).Semantic proximity Read ↗

HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.Semantic proximity Read ↗

HER-2/neu Expression in Salivary Duct Carcinoma: An Immunohistochemical and Chromogenic In Situ Hybridization StudySemantic proximity Read ↗

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialSemantic proximity Read ↗

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.